Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Patient group consists the consecutive patients with thyroid associated ophthalmopathy consulted by endocrinology department.
The control group was chosen among healthy volunteers who have
- no eye pathology,
- 20/20 vision (corrected or uncorrected),
- age and sex-matched with the patient group.
Exclusion Criteria:
For both groups, those who had
- significant sight impairment,
- high myopia ( < -5Diopters ),
- high hyperopia ( > +3Diopters ),
- optic disc anomaly,
- vitreoretinal interface disease,
- vascular and degenerative retinal diseases,
- cornea or lens opacity, ocular surgery history,
- glaucoma,
- neurological diseases that can affect the visual field,
- history of trauma, amblyopia,
- diplopia,
- keratitis,
- history of topical or systemic steroid
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Thyroid ophthalmopathy
Thyroid associated ophthalmopathy patients were measured by optical coherence tomography.
|
All groups were measured by optical coherence tomography.
|
|
Other: Control
Control group was consisted by age and sex- macthed healthy people adn they were measured by optical coherence tomography.
|
All groups were measured by optical coherence tomography.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Macular thickness
Time Frame: one year (between Jan 2012 and Jan 2013)
|
Macular thickness (micrometer) was measured by optical coherence tomography in patients and controls.
|
one year (between Jan 2012 and Jan 2013)
|
|
Retinal nerve fiber layer thickness
Time Frame: one year (between Jan 2012 and Jan 2013)
|
Retinal nerve fiber layer thickness (micrometer) was measured by optical coherence tomography in patient and control groups.
|
one year (between Jan 2012 and Jan 2013)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Optic disc parameters
Time Frame: one year (between Jan 2012 and Jan 2013)
|
Optic disc parameters (morphologic structures) were obtained by optical coherence tomography for both groups.
|
one year (between Jan 2012 and Jan 2013)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Nurşen ARITÜRK, Prof., Ondokuz Mayıs University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2013-379
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.